Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2021-12-28 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：股东减持股份结果公告
Major Shareholding Notification Classification · 95% confidence The document is a shareholder announcement regarding the results of a shareholding reduction plan by certain shareholders of Shanghai Medicilon Inc. It details the number of shares held before and after the reduction, the reduction plan, the implementation period, and the completion status. There is no financial report, earnings data, or management discussion. The document is a formal announcement of the results of a shareholding reduction, which fits the category of Major Shareholding Notification (MRQ). The document length is 2616 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is MRQ.
2021-12-28 Chinese
美迪西：关于2020年限制性股票激励计划第一个归属期第一次归属结果暨股份上市的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanghai Medicilon Inc. regarding the first vesting result of its 2020 restricted stock incentive plan and the listing of the vested shares. It details the decision-making process, the number of shares vested, the listing date, share source, and the impact on share capital and earnings per share. It also includes information about board and management changes related to the incentive plan. The document is a formal announcement about the completion and registration of restricted stock awards, not a full financial report or audit. It is not a report publication announcement since it contains substantive details about the stock incentive plan vesting and share issuance. The document fits best into the category of Capital/Financing Update (CAP) because it concerns share issuance related to an equity incentive plan and changes in share capital.
2021-12-10 Chinese
美迪西：第三届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution from the first meeting of the third Supervisory Board of Shanghai Medicilon Inc. It details the election of the chairman of the Supervisory Board and confirms the legality and attendance of the meeting. There is no financial data, audit information, or report content. It is a formal announcement related to board/management information, specifically about the Supervisory Board's composition and leadership. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or a notice of report publication, so it is not RPA or RNS.
2021-11-22 Chinese
美迪西：关于选举第三届监事会职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of employee representative supervisors to the company's third supervisory board. It includes details about the election process, the elected individuals, and their resumes. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The content focuses on board/management changes specifically related to the supervisory board composition. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA. It is not a regulatory filing or certification. Hence, the classification is MANG with high confidence.
2021-11-22 Chinese
美迪西：独立董事关于第三届董事会第一次会议相关事项的独立意见
Regulatory Filings
2021-11-22 Chinese
美迪西：关于选举董事长、监事会主席、董事会各专门委员会委员及聘任高级管理人员、证券事务代表的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from Shanghai Medicilon Inc. regarding the election of the chairman of the board, chairman of the supervisory board, members of the board's specialized committees, and the appointment of senior management and securities affairs representatives. It details the results of board meetings and appointments, referencing compliance with company law and company articles. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes and appointments in the company's board and senior management positions. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 4249 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is MANG with high confidence.
2021-11-22 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.